Isconova's liquidity guarantee

As a consequence of that shareholders corresponding to 97.4% of the share
capital have accepted the public tender offer by the US Nasdaq OMX-listed
vaccine company Novavax, and that the extended acceptance period ends on August
20, the last day of the liquidity guarantee for the Isconova share will be
August 15, 2013.

For more information, please contact:

Erik Bergman, CFO Isconova
Phone: +46 18 16 17 29
E-mail: erik.bergman@isconova.com

About Isconova

Isconova AB is a Uppsala, Sweden, based research and development company,
currently being acquired by Novavax, with a patented technology that enhances
the efficacy and duration of vaccines. Isconova develops vaccines together with
partners in veterinary and human markets, and since 2005, it has production and
sales of vaccine adjuvants for the veterinary market. www.isconova.com